US Edition
#Sensei Biotherapeutics Implements Reverse Stock Split Amidst Competitive Revenue Decline
Summary by csimarket.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
#Sensei Biotherapeutics Implements Reverse Stock Split Amidst Competitive Revenue Decline
On June 13, 2025, Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology firm focused on pioneering therapeutics for cancer treatment, announced a significant corporate action: a 1-for-20 reverse stock split of its issued and outstanding shares of common stock. This move, set to take effect at 5:00 p.m. Eastern Time on June 16, 2025, follows approval from the company's stockholders during its Annual Meeting on May 21, 2025. …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
